| Therapeutic | Bafisontamab |
| Target 1 | EGFR |
| Heavy Chain 1 | QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSS |
| Light Chain 1 | DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIK |
| 100% seqID Fv 1 Structure | 5sx4 [Fvs: HL, JI], 5sx5 [Fvs: HL, JK] |
| 99% seqID Fv 1 Structure | None |
| 95-98% seqID Fv 1 Structure | None |
| Target 2 | MET |
| Heavy Chain 2 | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGFSWVRQAPGQGLEWMGWISASNGNTYYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARVYADYADYWGQGTLVTVSS |
| Light Chain 2 | DIQMTQSPSSVSASVGDRVTITCRASQGINTWLAWYQQKPGKAPKLLIYAASSLKSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFGGGTKVEIK |
| 100% seqID Fv 2 Structure | None |
| 99% seqID Fv 2 Structure | None |
| 95-98% seqID Fv 2 Structure | None |
| 100% seqID Structure [Fv 1] | 5sx4 [Fvs: HL, JI] |
| 100% seqID Structure [Fv 1] | 5sx5 [Fvs: HL, JK] |
| There are no identical PDB matches to at least one Fv in this therapeutic. Click the links to build models with ABodyBuilder: [Fv 1] [Fv 2] |
Follow these links to our prediction tools:
| Format | Bispecific Mixed mAb and Fab |
| Isotype | G1;na |
| Highest Clinical Trial (Aug '23) | Phase-I/II |
| Estimated Status (Aug '23) | Active |
| Recorded Developmental Technology | na |
| INN Year Proposed | 2021 |
| INN Year Recommended | None |
| Companies Involved | EpimAb Biotherapeutics |
| Conditions Approved | na |
| Conditions Active | Non-small cell lung cancer, Solid tumours |
| Conditions Discontinued | na |
| Notes | Fv1 is Panitumumab |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
